Skip to main
UTHR

United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics (UTHR) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

United Therapeutics is a promising investment due to its strong performance in TETON-1 data for the use of Tyvaso in IPF, potential for nebulized Tyvaso to be used as monotherapy, and expected success in the regulatory filing for nebulized Tyvaso. Factors such as the company's strong IPF pipeline, the FDA's new single pivotal trial policy, and the potential for ralinepag to replace JNJ's selexipag with better convenience and tolerability, further support our positive outlook.

Bears say

United Therapeutics is facing potential challenges in expanding its Tyvaso product into treatments for pulmonary fibrosis, as there is uncertainty about how much of the observed benefit is due to direct antifibrotic activity versus treatment of accompanying pulmonary vascular disease. Additionally, while management has high hopes for its TRESMI drug, the FDA's support for its filing in different markets is unclear, leaving further potential for disappointment. This, along with uncertainties around upcoming catalysts and the company's compressed multiples compared to its peers, leads to a negative outlook on UTHR's financial future.

United Therapeutics (UTHR) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About United Therapeutics (UTHR) Forecast

Analysts have given United Therapeutics (UTHR) a Buy based on their latest research and market trends.

According to 11 analysts, United Therapeutics (UTHR) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $611.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $611.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

United Therapeutics (UTHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.